Shook David 4
4 · Lyell Immunopharma, Inc. · Filed Feb 11, 2026
Research Summary
AI-generated summary of this filing
Lyell (LYEL) CMO David Shook Receives 50,000-Share Award
What Happened
David Shook, Chief Medical Officer of Lyell Immunopharma (LYEL), was granted a derivative award for 50,000 shares on 2026-02-10. The Form 4 reports an acquisition price of $0.00 (the filing classifies this as an award/derivative), so no cash was paid at grant. The filing does not report an immediate sale or exercise of shares.
Key Details
- Transaction date: 2026-02-10; transaction type: Grant/Award (derivative), reported 2026-02-11.
- Reported acquisition price: $0.00 (derivative award).
- Shares involved: 50,000.
- Shares owned after transaction: not specified in the provided excerpt of the filing.
- Vesting (per footnote F1): 12.5% vests six months after the Vesting Commencement Date (Feb 9, 2026), then an additional 1/48th of the total shares vests monthly thereafter until fully vested, subject to continued service.
- Timeliness: Filing appears timely (Form date 2026-02-11 for a 2026-02-10 report).
Context
This is a compensation-related derivative award (likely an option or RSU-style grant) rather than an open‑market purchase or sale, so it’s primarily a personnel/compensation event—not an immediate buy/sell signal. No exercise or sale was reported with this grant. For full details (exercise price, total holdings, plan terms, and potential dilution), review the complete Form 4 and the company’s equity plan disclosures.
Insider Transaction Report
- Award
Option (right to buy)
[F1]2026-02-10+50,000→ 50,000 totalExercise: $23.71Exp: 2036-02-09→ Common Stock (50,000 underlying)
- 21,900
Common Stock
Footnotes (1)
- [F1]Twelve and one-half percent (12.5%) of the total number of shares of Common Stock subject to the option will be vested and exercisable on the date that is six (6) months after February 9, 2026 (the "Vesting Commencement Date") and thereafter, an additional one fortyeighth (1/48th) of the shares will become vested and exercisable monthly on the same day as the Vesting Commencement Date (or, if there is no such corresponding day for a given month, on the last day of such month), until the option has become vested and exercisable with respect to one hundred percent (100%) of the shares, subject to the Reporting Person providing service to the Issuer through each applicable vesting date.